迈入减肥药2.0时代:从减重到增肌,催化剂来了?

华尔街见闻
03 Jun

市场是不是应该期待6月下旬的ADA(美国糖尿病学会年会)上,有新的大额BD交易爆发? 2025年6月2日,翰森制药与美国再生元(Regeneron)共同宣布一项重磅许可合作:再生元以8000万美元首付款、最高19.3亿美元里程碑付款获得翰森在研GLP-1/GIP双受体激动剂HS-20094在大中华区以外的全球独家开发与商业化权利。 HS-20094是一款每周皮下注射的候选药物,在超过千例受试者的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10